Regenerative dermatology, evidence in.
Exosomes, PRP, amniotic matrices, and photobiomodulation for wound care, scarring, alopecia, and inflammatory dermatoses — with the delivery devices to match.
Dermatology sits at the intersection of medical and aesthetic regenerative medicine. DRS supplies MISEV-compliant exosome products, amniotic tissue for chronic wound care, PRP for hair restoration, and LLLT / HPLT platforms for inflammatory and pigmentary conditions — with staff training and marketing-safe claims scaffolding.
Common indications we support
- Chronic wounds (venous, pressure, diabetic)
- Hypertrophic and atrophic scarring
- Androgenic and telogen effluvium alopecia
- Inflammatory conditions (acne, psoriasis)
- Pigmentary disorders (vitiligo, PIH)
- Post-procedure recovery and rejuvenation
Devices, biologics & protocols for this specialty
~85% DFU closure at 12 weeks with weekly application versus ~50% SOC.
Amniotic productsApplied topically after microneedling, fractional dermal infusion, or laser resurfacing.
Exosome catalogAutologous PRP prep pathways with androgenic alopecia protocols and injection templates.
PRP kitsPhotobiomodulation platforms for inflammatory, pigmentary, and post-procedure indications.
Photobiomodulation devicesPublications relevant to this specialty
Curated evidence from our Publications library that references Regenerative dermatology, evidence in.
- Photobiomodulation · Class IVHigh Power Laser Therapy (HPLT)
Class IV therapeutic lasers deliver 10 – 30 W of near-infrared light at 810 – 1,064 nm, driving photobiomodulation of cytochrome c oxidase and short-term ATP surge. The 2026 evidence includes controlled trials from major U.S. medical schools, the DoD, VA rehabilitation programs, and adoption by 40+ NFL, NBA, and MLB training rooms.
Why it's relevant: LLLT/HPLT applications in acne, psoriasis, vitiligo, and PIH.
Read the publication - Biologic dressings · Regenerative matricesAmniotic Tissue Allografts
Amniotic tissue has been used clinically for more than 100 years, since Davis first documented amniotic-membrane skin grafts in 1910. Modern dehydrated and cryopreserved allografts retain growth factors, cytokines, and extracellular matrix that support wound healing, ophthalmic reconstruction, and orthopedic soft-tissue repair.
Why it's relevant: ~85% DFU closure at 12 weeks vs. ~50% SOC.
Read the publication - Extracellular vesicles · Standardized reportingExosome Characterization & MISEV 2023 Standards
Exosomes are 30 – 150 nm extracellular vesicles that carry proteins, lipids, and RNA cargo between cells. MISEV 2023 — the third revision of Minimum Information for Studies of Extracellular Vesicles from the International Society for Extracellular Vesicles — is the current global standard for characterization and reporting.
Why it's relevant: Lot-level CoAs with tetraspanin and negative-marker workup.
Read the publication
Frequently asked questions
- What dermatologic conditions do regenerative protocols target?
- Androgenetic alopecia, scarring and acne sequelae, photoaging, chronic non-healing wounds, and post-procedure recovery are the most common indications in dermatology practices.
- How strong is the evidence for PRP in hair loss?
- Randomized and split-scalp studies consistently show increased hair density and caliber in androgenetic alopecia over 3 to 6 months, with best results when combined with standard medical therapy.
- Are exosome products FDA-approved?
- No exosome product is FDA-approved for injection. Topical post-procedure use is the common pathway, and sourcing documentation matters. We help practices understand exactly what they are buying.
- Which devices do dermatology practices start with?
- Most begin with microneedling plus fractional dermal infusion and a low-level laser platform, then add focused shockwave or high-power laser as case volume grows.
Bring regenerative medicine into your practice.
Talk with our team about biologics, devices, or an AI-powered peptide protocol tailored to your patients.